Partner & Licensees


  • 2022

    20th anniver­sary

  • 2021

    VLP purifi­ca­tion patent grant­ed in EU and US

  • 2019

    acqui­si­tion of Split­Core technology

  • 2018

    15 L pilot scale facil­i­ty established

  • 2017

    new VLP patent grant­ed in EU

  • 2016

    col­lab­o­ra­tion with Bio­Sun on devel­op­ment of a Gar­dasil-like HPV vaccine

  • 2015

    first col­lab­o­ra­tions in the vet­eri­nary vac­cine field

  • 2014

    SUN Glob­al FZE as strate­gic investor 

  • 2013

    bio-sim­i­lar tech trans­fers to Viet­nam, Thai­land and Indonesia

  • 2012

    first col­lab­o­ra­tions in the area VLP based vaccines

  • 2011

    first bio-sim­i­lar tech­nol­o­gy trans­fers & estab­lish­ment of secre­to­ry E. coli plat­form

  • 2010

    acqui­si­tion of the patent fam­i­ly „VLP vaccines“

  • 2008

    estab­lish­ment of process devel­op­ment group, sec­ond chap­er­one patent

  • 2007

    move in facil­i­ty in Lan­gen­feld (850 sqm labs and offices)

  • 2006

    first patent grant­ed (chap­er­one)

  • 2002

    foun­da­tion as con­tract R&D com­pa­ny and first license deals


from left to right: Volk­er Jen­zelews­ki, Petra Zim­mer, Michael Pio­ntek, Melanie Pio­ntek, Michael Weniger

Dr. Michael Pio­ntek (Man­ag­ing Director)

Michael Pio­ntek is founder of ARTES and Man­ag­ing Direc­tor. He has more than 20 years expe­ri­ence in con­tract R&D, process devel­op­ment and com­pa­ny man­age­ment. For­mer­ly he was Head of Process Devel­op­ment and Man­ag­ing Direc­tor at Rhein Biotech GmbH. In this time, he was respon­si­ble for process and prod­uct devel­op­ment as well as for tech­nol­o­gy trans­fer of pro­duc­tion process­es in Europe, Asia, South Amer­i­ca and North Africa.

P: +49 (0) 2173 27587–11
M: +49 (0) 173 213 26 15
E: m.piontek(at)

Dr. Melanie Pio­ntek (Busi­ness Devel­op­ment Director)

Melanie Pio­ntek holds a PhD in biol­o­gy and is spe­cial­ized in pro­tein chem­istry. She is in charge of busi­ness devel­op­ment for ARTES since 2006. Before that, she worked 8 years in region­al devel­op­ment com­pa­nies and tech­nol­o­gy trans­fer agen­cies with the focus on sup­ply­ing biotech com­pa­nies with mar­ket­ing and net­work­ing oppor­tu­ni­ties, as well as with busi­ness devel­op­ment support.

P: +49 (0) 2173 27587–12
M: +49 (0) 177 501 47 48
E: piontek(at)

Dipl.-Biol. Volk­er Jen­zelews­ki (Direc­tor Technology)

Volk­er Jen­zelews­ki holds a degree in biol­o­gy and start­ed his pro­fes­sion­al career in 1993 at Rhein­Biotech GmbH. Assum­ing posi­tions of increas­ing respon­si­bil­i­ty in tech­ni­cal man­age­ment and GMP-man­u­fac­tur­ing he was final­ly direct­ing process devel­op­ment and head­ing GMP man­u­fac­tur­ing. In 2010 he stepped into the field of advanced ther­a­py med­i­c­i­nal prod­ucts as Man­ag­ing Direc­tor of EUFETS GmbH, an inter­na­tion­al­ly oper­at­ing CDMO. In 2014 he joined ARTES Biotech­nol­o­gy GmbH as Direc­tor of Technology.

P: +49 (0) 2173 27587 ‑19

M: + 49 (0) 152 54715382
E: v.jenzelewski(at)

Dipl.-Ing. Michael Weniger (Head of Process Development)

Michael Weniger holds a degree as Grad­u­ate Engi­neer Biotechnology/Biochemistry. For­mer­ly he was Project Leader and Senior Engi­neer Process Devel­op­ment at Rhein Biotech GmbH. He was involved in suc­cess­ful tech­nol­o­gy trans­fer of cGMP pro­duc­tion process­es to South Amer­i­ca, Korea and Egypt.

His expe­ri­ence are in the field of up- and down­stream pro­cess­ing of bac­te­r­i­al process­es, opti­miza­tion of fer­men­ta­tion process­es with sub­se­quent devel­op­ment of pro­tein iso­la­tion and purifi­ca­tion strate­gies until gen­er­a­tion of puri­fied final bulk. He has expe­ri­ence in cGMP pro­duc­tion of a Phase IIIa prod­uct and deep know how in qual­i­fi­ca­tion (DQ/IQ/OQ) and val­i­da­tion (PQ, clean­ing val­i­da­tion) of equip­ment and process with the appro­pri­ate cGMP documentation.

P: +49 (0) 2173  27587 ‑20
E: m.weniger(at)

Dipl.-Ing. Petra Zim­mer (Finance Director)

Petra Zim­mer is in charge of finances for ARTES. She is qual­i­fied as tax-advi­sor and runs her own busi­ness since more than 20 years, main­ly with clients from the biotech branch. In between she has been full-time Chief Finan­cial Offi­cer of Rhein Biotech GmbH for five years. She holds a Mas­ter Degree in Machin­ery Con­struc­tion and start­ed her busi­ness expe­ri­ence with Arthur Ander­sen where she left as Manager.

P: +49 (0) 2173  27587 ‑22
E: p.zimmer(at)

Fine Art of Biotechnology

ARTES Biotech­nol­o­gy is a glob­al­ly work­ing, well estab­lished and reli­able tech­nol­o­gy provider for recom­bi­nant pro­tein pro­duc­tion. We devel­op micro­bial cell lines and process­es for vac­cines, bio­phar­ma­ceu­ti­cals, biosim­i­lars and enzymes and offer ready-to-trans­fer process­es for a wide range of products. 

Our high expe­ri­ence team is avail­able for tai­lor-made projects for the most effi­cient solu­tion. We are experts in trou­ble-shoot­ing and in the set-up of man­u­fac­tur­ing processes.

All plat­form tech­nolo­gies (cell lines and vac­cines) ensure free­dom-to-oper­ate and are pro­tect­ed by patents and trade secrets. ARTES is avail­able to nego­ti­ate exclu­sive license terms.

WHO rec­om­men­da­tion, inter­na­tion­al reg­is­tra­tions, FDA approvals and GRAS cer­ti­fi­ca­tions are part of the track record achieved in our inter­na­tion­al col­lab­o­ra­tions. Large-scale man­u­fac­tur­ing and full ana­lyt­ics in accor­dance with cGMP guide­lines are war­rant­ed in col­lab­o­ra­tion with partners.


ARTES Biotech­nol­o­gy GmbH
Elis­a­beth-Sel­bert-Str. 9
40764 Langenfeld

P: +49 (0) 2173 27587–0
F: +49 (0) 2173 27587–77

E: info (at)